Backs FY25 revenue view of $1.15B-$1.225B, consensus $1.18B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- HALO Upcoming Earnings Report: What to Expect?
- Halozyme assumed with an Overweight at Morgan Stanley
- Halozyme Board Member Connie Matsui Steps Down
- Halozyme’s Strategic Advancements and Market Potential Justify Buy Rating
- Positive Regulatory Developments and Revenue Growth Potential Support Buy Rating for Halozyme Therapeutics